HD-OPM Archive

Omega-3 supplements and icosapent ethyl

What the group's posts say about fish oil and prescription purified EPA (icosapent ethyl), including what the trials and meta-analyses show for heart attacks and plaque, how doses relate to the atrial fibrillation (AFib) signal, and how to think about practical choices.

16 min read44 group posts cited37 studies discussed3 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • A 2021 meta-analysis of 40 randomized trials (135,267 people) found omega-3 EPA/DHA lowered heart attack risk by 13% and fatal heart attack by 35%, with 1,000-2,000 mg/day suggested by its authors.
  • Prescription icosapent ethyl (purified EPA, 4 g/day) is FDA-approved to reduce cardiovascular risk in people with triglycerides of 150 mg/dL or more who are on a statin and have established disease or diabetes plus risk factors; REDUCE-IT showed a 25% relative reduction in major events.
  • In the 80-person EVAPORATE trial, 4 g/day of icosapent ethyl for 18 months reduced coronary plaque compared with placebo.
  • Higher doses carry a real AFib signal, with a 2021 meta-analysis finding about 25% higher AFib risk overall and 49% above 1 g/day, while a 2026 update suggests the problem is confined to high doses in people already at high cardiovascular risk.
  • Prescription-level doses (about 4 g/day) lower elevated triglycerides by roughly 20-30%, but blood pressure effects are small (about 2.6 mmHg systolic).
  • Group admins repeatedly advise talking to a doctor before starting high-dose fish oil, especially with AFib risk.
In this summary
  1. What omega-3s are and what they actually do
  2. What the evidence shows for heart events
  3. Atrial fibrillation: the main safety question
  4. Nuances, controversies and common misconceptions
  5. What this means for you
  6. Frequently asked questions
  7. The evidence behind this summary

Fish oil is one of the most discussed supplements in the group, and the honest answer to "does it work?" depends on which product, which dose and which person. Taken together, the pooled randomized trials posted in the group point to a modest reduction in heart attack and coronary events from marine omega-3s (EPA and DHA).12 A purified, prescription form of EPA called icosapent ethyl (brand name Vascepa) has the strongest outcome data and a formal regulatory indication.3

The main caution is atrial fibrillation (AFib), an irregular heart rhythm. Higher doses appear to raise AFib risk, and the effect looks most relevant in people who already have high cardiovascular risk.4 Louis Nervegna, the group's admin who posts most of this material, adds the same warning to nearly every high-dose post: talk to your doctor before starting high doses of fish oil.56

This article walks through what omega-3s are, what the trials show, where the evidence is disputed or observational, and how group members approach dosing. It is a summary of what was posted, not medical advice.

13%fewer heart attacks with EPA plus DHA across 40 randomized trials (135,267 people)1
25%fewer major cardiovascular events with prescription EPA (icosapent ethyl) in REDUCE-IT3
49%higher atrial fibrillation risk at doses above 1 g a day in a 2021 meta-analysis4
4.12%average US omega-3 index; fewer than 1 in 50 people reach 8%7

What omega-3s are and what they actually do

The two long-chain marine omega-3 fatty acids are EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). They become part of the phospholipid membranes that surround cells throughout the body, and DHA is especially concentrated in the brain and retina. ALA, the plant omega-3 found in flax and walnuts, is also essential, but humans convert only small amounts of it into EPA and DHA.8

One post pushes back on the idea that omega-3s are a generic "anti-inflammatory". Its argument is that the biology is more specific, and the clearest clinical effect is on triglycerides: at prescription doses of about 4 g/day, omega-3s typically lower elevated triglycerides by roughly 20-30%, with larger reductions possible when baseline levels are very high. That post stresses this is a pharmacologic dose and should not be confused with an ordinary fish-oil capsule or a serving of fish.8

Other measured effects are smaller:

  • Blood pressure. A dose-response meta-analysis of 71 randomized trials found that 2-3 g/day of combined EPA and DHA lowered systolic pressure by about 2.6 mmHg and diastolic by about 1.6-1.8 mmHg on average, with larger effects in people with hypertension or elevated lipids.8
  • Inflammation markers. In a meta-analysis of lipid-lowering therapies, fish oil lowered hsCRP (a blood marker of inflammation) by about 12.8%, compared with 17.3% for statins and 20% for bempedoic acid.9 The abstract quoted in that post says omega-3 fatty acids reduce CRP independently of LDL-C reductions.9
  • Platelets. A review of functional foods notes that EPA and DHA reduce platelet aggregation, though results varied by dose and population.10
Fish oil lowers hsCRP about as much as some lipid drugsAverage fall in hsCRP (an inflammation marker), meta-analysis of randomized trials of lipid-lowering therapies
Bempedoic acid−20%
Statins−17.3%
Fish oil (omega-3)about −12.8%
Fibrates−10.3%
Ezetimibe−3.2%
Averages across different trials and populations. Fish oil was given in the post as a comparison figure. Source: 9
Show data
Value
Bempedoic acid−20%
Statins−17.3%
Fish oil (omega-3)about −12.8%
Fibrates−10.3%
Ezetimibe−3.2%

What the evidence shows for heart events

Pooled trials of EPA and DHA

The most-cited pooled analysis in the group is a 2021 meta-analysis and meta-regression published in Mayo Clinic Proceedings. It covered 40 randomized trials with 135,267 participants and reported:1

  • Heart attack: relative risk 0.87 (95% CI 0.80 to 0.96), number needed to treat 272, rated high certainty.
  • Coronary heart disease events: relative risk 0.90, number needed to treat 192, high certainty.
  • Fatal heart attack: relative risk 0.65, number needed to treat 128, moderate certainty.
  • Coronary heart disease mortality: relative risk 0.91, number needed to treat 431, low certainty.
  • Overall cardiovascular events (a broad composite): relative risk 0.95 (0.90 to 1.00), which was not statistically significant.
Omega-3 cut heart attacks, not all cardiovascular eventsRelative risk with EPA/DHA supplements versus control, meta-analysis of 40 randomized trials (135,267 participants, 2021)
interval clear of 1interval includes 1 (no clear difference)95% confidence interval
Heart attack0.87 (0.80–0.96)
Coronary heart disease events0.90 (0.84–0.97)
Fatal heart attack0.65 (0.46–0.91)
Coronary heart disease death0.91 (0.85–0.98)
Broad cardiovascular events composite0.95 (0.90–1.00)
Certainty was high for heart attack and coronary events, moderate for fatal heart attack and low for coronary death. Source: 1
Show data
Relative risk (log scale)95% CI
Heart attack0.870.80–0.96
Coronary heart disease events0.900.84–0.97
Fatal heart attack0.650.46–0.91
Coronary heart disease death0.910.85–0.98
Broad cardiovascular events composite0.950.90–1.00

The authors found the effect was dose-dependent for heart attack and cardiovascular events, with each additional 1 g/day associated with a 9% lower risk of heart attack, and suggested 1,000-2,000 mg/day of combined EPA and DHA.1 Louis called the 35% reduction in fatal heart attacks "especially impressive" compared with other interventions, and also added a warning that several trials showed a small increase in AFib at high doses.1

A separate JACC systematic review of 884 trials across 27 micronutrients (883,627 participants) found a similar signal for omega-3: cardiovascular mortality relative risk 0.93, heart attack 0.85 and coronary events 0.86. The same review found no effect of vitamin C, D, E or selenium on cardiovascular disease or type 2 diabetes, and an increase in mortality with beta-carotene.2

VITAL

The Harvard Gazette profile of JoAnn Manson, quoted in the group, describes the VITAL randomized trial of about 25,000 men and women aged 50 and older. It reported in 2018 that fish-oil omega-3s were associated with a 28% reduction in heart attack, and about 40% among people who reported minimal fish in their diet.11 This was a post quoting a news profile rather than the paper, so the group's summary does not give confidence intervals.

REDUCE-IT and icosapent ethyl

Icosapent ethyl is a highly purified ethyl ester of EPA. A post summarizing its FDA status says the agency continues to approve it to reduce cardiovascular risk, citing REDUCE-IT, which showed a 25% relative risk reduction in major adverse cardiovascular events. The label extension dates to December 2019.3 The indication is as an add-on to maximally tolerated statin therapy in adults with triglycerides of 150 mg/dL or more and either established cardiovascular disease, or diabetes plus two or more additional risk factors.3 An earlier post and the Harvard Health text it quoted describe the drug as lowering heart attack and stroke risk by 26% in people at high risk;5 the two figures differ slightly in the posts, so it is safest to say "roughly a quarter".

Louis emphasizes that Vascepa is high-dose EPA from fish oil, and that it is FDA-approved to lower cardiovascular risk, not just to lower triglycerides.5 Studies presented at the 2025 American College of Cardiology meeting were described as strengthening the case that purified EPA lowers heart attack and stroke risk even in patients already at an appropriately low LDL target, especially if triglycerides remain elevated.12

Plaque: EVAPORATE

The EVAPORATE trial (published in the European Heart Journal in 2020) enrolled 80 people with coronary artery disease, most of whom had diabetes and were on a statin, with triglycerides of 135 to 499 mg/dL. Half were randomized to 4 g/day of icosapent ethyl and half to placebo. After 18 months, imaging showed less unstable plaque and lower total plaque volume with the drug.5 A summary by group member Daniel Chong puts the reduction in vulnerable plaque at 17%,13 and Gokhan Can's ranking of plaque-regression strategies rates high-dose EPA as "likely helpful", noting that EVAPORATE showed markedly greater regression over 18 months and that another trial, CHERRY, also found greater regression with EPA.14

Louis includes high-dose EPA on his list of at least six strategies that have reversed plaque in randomized trials, alongside major weight loss, a Mediterranean or DASH diet, LDL-lowering drugs, colchicine and exercise.15 Other posts in the group repeat this list.1617 It is worth keeping the scale in mind: EVAPORATE was a small trial, and participants all had elevated triglycerides at the start.5

A member case report was shared as an illustration, not as evidence. A group member described a soft plaque with 70% stenosis in the left anterior descending artery that was no longer visible on a repeat coronary CT angiogram after roughly six to seven months on 6 g/day of over-the-counter EPA with a baby aspirin and no statin.6 The member himself wrote that he does not recommend others copy this without medical supervision because high-dose EPA can be dangerous for some, citing AFib and bleeding risks.6

Atrial fibrillation: the main safety question

The group does not downplay this. Louis wrote that the AFib risk from high doses "is real and should be taken seriously".4 The numbers he shared:

  • A 2021 meta-analysis of seven randomized trials (81,210 participants), published in Circulation, found omega-3 supplementation raised AFib risk by 25% overall. Doses above 1 g/day were associated with a 49% higher risk, and each additional gram per day raised the hazard by 11%.4
  • A 2026 updated meta-analysis of 35 trials (114,592 people) in Circulation: Arrhythmia and Electrophysiology concluded that high-dose EPA/DHA is associated with increased AFib in people at high cardiovascular risk, while low-dose EPA/DHA did not appear to raise AFib risk even in high-risk populations. Louis notes there was no increased risk from higher doses in people not at high cardiovascular risk.4
  • The FDA-label summary for icosapent ethyl reports AFib or flutter requiring hospitalization in 5.3% versus 3.9% of participants, and bleeding in 11.8% versus 9.9%.3
Prescription EPA came with more AFib and bleedingShare of participants with each side effect in the icosapent ethyl trials, as summarized from the FDA label
Icosapent ethylPlacebo
Atrial fibrillation or flutter needing hospital care5.3%3.9%
Bleeding events11.8%9.9%
Source: 3
Show data
Icosapent ethylPlacebo
Atrial fibrillation or flutter needing hospital care5.3%3.9%
Bleeding events11.8%9.9%

The shared explainer proposes that omega-3s integrate into cardiac cell membranes and change ion-channel behaviour.4 A video by fatty acid researcher Bill Harris was shared with the comment that whether fish oil causes or prevents AFib "is complicated" and may depend on dose and risk level.18

Bleeding has a longer-term perspective too. A 21-year Danish cohort of 54,546 adults aged 50 to 65 measured EPA and DHA in fat tissue and found that people with the highest EPA had a 36% lower risk of bleeding stroke; DHA was neutral and ALA was linked to a 32% higher risk, which the post says needs confirmation. The same post says pooled analysis of 11 randomized trials with more than 120,000 people found no increased brain bleeding, apart from a small added risk with high-dose prescription EPA. It is observational, so it cannot prove cause.19

Nuances, controversies and common misconceptions

Was the REDUCE-IT placebo a problem?

REDUCE-IT used mineral oil as the placebo, and some cardiologists argued the placebo may have mildly inflated the drug's apparent benefit. The post on FDA status says the agency concluded the efficacy was statistically and clinically significant, and that by its analysis a harmful placebo effect could account for at most a 2-5% relative risk difference.3

EPA alone, DHA, or both?

Gokhan describes aiming for 3 g EPA, 1 g DHA and 4.9 g total omega-3 per day by combining mixed EPA-DHA capsules with pure EPA, and notes that EPA appears to be the main contributor to vascular health but DHA may also help.20 The plaque case report above used EPA alone, with the member explicitly avoiding DHA.6 The group's trial results involve different products: icosapent ethyl in REDUCE-IT and EVAPORATE is pure EPA, while the 40-trial meta-analysis pooled EPA and DHA together.15 There is no head-to-head comparison in these posts.

The omega-3 index and "like smoking" claims

The omega-3 index is the share of red blood cell membranes made up of EPA and DHA. A set of posts relays claims, from FoundMyFitness and others, that an index below 4% carries a mortality risk comparable to smoking, and that about 2 g/day of EPA plus DHA raises the index from 4% to 8%, associated with roughly five more years of life expectancy.212223 A Rhonda Patrick keynote summary adds that an 8% versus 4% index was associated with 90% lower risk of sudden cardiac death.24 Louis labels this research as mostly observational, "but compelling", with some of it from the Framingham Heart Study.22

A later post cites NHANES data putting the US average index at 4.12%, with fewer than 1 in 50 reaching 8%. People in the highest fifth of the index had lower all-cause mortality in a 2,500-person cohort and a 42,466-person pooled analysis, and in Framingham the index predicted death better than cholesterol. The post itself says these are associations, not proof that raising the index saves lives.7 The same post says the dose needed to reach 8% from a 4% start is about 2,000 mg/day, and about 1,100 mg from 6%.7 A video from a company that sells the index test argues it may predict risk better than cholesterol; the post gives no numbers and the source has a commercial interest.25 Targets also vary among individuals: Peter Attia reportedly aims for a red-cell EPA+DHA level near 12% using about 2 g EPA and 1.5 g DHA daily, a personal regimen rather than evidence.26

The omega-3 index (the share of red blood cell fat that is EPA and DHA) as shown in the shared evidence review: below 4% is labelled undesirable, 4–8% intermediate and 8% or more desirable, with the US average at 4.12%.
The omega-3 index (the share of red blood cell fat that is EPA and DHA) as shown in the shared evidence review: below 4% is labelled undesirable, 4–8% intermediate and 8% or more desirable, with the US average at 4.12%.7

Oxidized fish oil

Many people worry that rancid or oxidized capsules do harm. Louis shared Bill Harris's argument that this is likely not harmful, and that oxidized oil may be slightly less effective.27 He describes a human trial in which fish oil was deliberately super-oxidized and fed for 7 weeks, with no difference in oxidation, peroxidation or inflammation markers, nor in glucose, lipids or liver enzymes versus non-oxidized oil.28 Another post says randomized trials show oxidized fish oil does not worsen these markers.29

Omega-3s and the brain: mixed results

  • DHA in APOE4 carriers. The PREVENT-E4 trial gave 2,000 mg/day DHA for two years to 365 adults aged 55 to 80 who rarely ate fish (47% APOE4 carriers). There was no difference in cognition or hippocampal volume on MRI. DHA reached spinal fluid equally in APOE4 carriers and non-carriers.30 Louis stresses that the trial was small, short and designed mainly to test brain penetration, so cognitive results are exploratory, and that APOE4 carriers with the highest DHA-to-arachidonic-acid ratio declined less.3031
  • Observational signals can mislead. An observational ADNI study reported faster cognitive decline in fish oil users. Hussein Yassine, a USC neurologist, argues reverse causation is the likeliest explanation, as people who notice early memory problems start supplements.32
  • Plant omega-3 trial. A Rutgers trial is testing ALA in APOE4 carriers with mild cognitive impairment, on the rationale that ALA enters the brain more easily in these carriers.33

Vegans and omega-3

Joel Fuhrman argues that vegans converting plant ALA poorly may have an omega-3 index below 4% and should use algae-based DHA and EPA to reach 6-9%, but the post comes from a promotional blog without cited studies.34

Aging, cancer and other findings

Louis has shared several other results, which are interesting but mostly use surrogate or secondary outcomes:

  • In the 3-year DO-HEALTH trial of 2,147 adults aged 70 or older, 1 g/day of omega-3 slowed three epigenetic aging clocks by about three months, with nearly four months when combined with vitamin D and exercise. The trial also reported 10% fewer falls and 13% fewer infections with omega-3.35 A follow-up post hoc analysis in 777 adults found omega-3 slowed three of four methylation clocks, which are surrogate markers.36
  • The combination of vitamin D3 2,000 IU/day, omega-3 1 g/day and home exercise was associated with a 61% reduction in invasive cancer (4 cases versus 12 on placebo, number needed to treat 35), a small number of events.3738
  • In VITAL, omega-3 at 1 g/day showed no effect on leukocyte telomere length.39
  • A 2022 meta-analysis of eight trials found 1-2 g/day reduced premenstrual syndrome severity, though heterogeneity was noted.40
  • A 2025 review of 33 systematic studies found little evidence that omega-3 supplements improve lean mass, strength or physical function,41 though a small 8-week krill oil trial during alternate-day fasting reported less fat-free mass loss (-0.2 kg versus -1.2 kg).42

What this means for you

These points reflect what the group's posts say; they are not individual medical advice.

  • Know your category. The strongest outcome evidence for a single product belongs to prescription icosapent ethyl, at 4 g/day, in people on statins with elevated triglycerides and established disease or diabetes.35
  • Lower doses have the best-supported balance. The 40-trial meta-analysis suggested 1,000-2,000 mg/day of EPA plus DHA,1 and the 2026 AFib update found no AFib increase at low doses even in high-risk people.4
  • Higher doses call for medical conversation. The group's admins consistently recommend talking to a doctor before starting high-dose fish oil, especially for anyone at higher risk of AFib.15
  • Consider bleeding and other medicines. Bleeding events were somewhat more common on icosapent ethyl,3 and the member case report mentions both AFib and bleeding as risks.6
  • Take it with a fat-containing meal. Louis shared Lawson and Hughes (1988): ethyl-ester EPA was absorbed at about 20% with a low-fat meal (8 g) and about 60% with a high-fat meal (44 g), while triglyceride-form fish oil was already around 69% absorbed with a low-fat meal.43
  • Food counts too. The 2025 ACC scientific statement on inflammation emphasizes lifestyle measures, including two to three meals per week of fatty fish high in EPA and DHA, alongside exercise and a Mediterranean or DASH diet.44
  • Treat omega-3 as one layer, not a replacement. Plaque-regression summaries rank statins, PCSK9 inhibitors and ezetimibe as having the strongest evidence, with high-dose EPA below them.14
EPA absorption by supplement form and meal fat (Lawson and Hughes, 1988), as charted in a shared post: ethyl esters were absorbed about 20% with a low-fat meal and about 60% with a high-fat meal, while triglyceride-form oil was absorbed 69% with a low-fat meal and 90% with a high-fat one.
EPA absorption by supplement form and meal fat (Lawson and Hughes, 1988), as charted in a shared post: ethyl esters were absorbed about 20% with a low-fat meal and about 60% with a high-fat meal, while triglyceride-form oil was absorbed 69% with a low-fat meal and 90% with a high-fat one.43

Frequently asked questions

Does ordinary fish oil prevent heart attacks?

Pooled analyses of randomized trials suggest a modest reduction: heart attack risk fell 13% and fatal heart attack 35% in one meta-analysis, though overall cardiovascular events were not significantly reduced.1 Another large review reported a heart attack relative risk of 0.85.2

Is over-the-counter EPA the same as Vascepa?

Vascepa is a highly purified EPA ethyl ester used in REDUCE-IT.3 The posts do not compare it head-to-head with supplements, and the member case report used over-the-counter EPA at 6 g/day, which is not a trial result.6

How high a dose raises AFib risk?

In the 2021 meta-analysis, doses above 1 g/day were linked to a 49% higher AFib risk and each additional gram per day to an 11% higher hazard. The 2026 update found the increase in high-risk people at higher doses but not at low doses.4

Does fish oil lower triglycerides and blood pressure?

At about 4 g/day, omega-3s lower elevated triglycerides by roughly 20-30%. A 2-3 g/day dose lowers systolic blood pressure by only about 2.6 mmHg on average.8

Is oxidized fish oil dangerous?

Group posts relay trial evidence that deliberately super-oxidized fish oil did not worsen oxidation, inflammation, lipid or liver markers over 7 weeks, and that it may be only slightly less effective.2728

The evidence behind this summary37 studies · 8 meta-analyses · 16 trials · 5 observational

The 44 group posts cited above discuss 37 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 8Randomized trials 16Observational studies 5Reviews & guidelines 4Other sources 4

Strongest evidence discussed

All 37 studies and sources
Sources from the group (44)
  1. Omega-3 supplementation across 40 RCTs lowered heart attack 13% and fatal heart attack 35% Louis Nervegna · Dec 20, 2025 · Facebook
  2. Review of 884 supplement RCTs: omega-3, folic acid and CoQ10 helped; beta-carotene harmed Louis Nervegna · Nov 30, 2023 · Facebook
  3. FDA keeps icosapent ethyl (Vascepa) approved for CV risk reduction based on REDUCE-IT Louis Nervegna · May 24, 2026 · Facebook
  4. High-dose omega-3 raises AFib risk in high-CVD-risk people, not at low doses (2026) Louis Nervegna · Sep 16, 2026 · Facebook
  5. EVAPORATE: high-dose EPA reversed plaque in patients with triglycerides above 135 mg/dL Louis Nervegna · May 04, 2026 · Facebook
  6. Group member reports 'widowmaker' soft plaque regression on 6 g/day EPA, citing EVAPORATE Louis Nervegna · May 04, 2026 · Facebook
  7. Omega-3 index tracked mortality like classic risk factors; high intake may raise AFib Louis Nervegna · Jul 17, 2026 · Facebook
  8. Omega-3 effects explained: triglycerides fall 20-30% at 4 g/day, blood pressure modestly Louis Nervegna · Sep 30, 2026 · Facebook
  9. Statins, bempedoic acid, ezetimibe, fibrates and PCSK9 inhibitors all lower hsCRP Louis Nervegna · Dec 28, 2025 · Facebook
  10. Review: functional foods as safer alternatives to antiplatelet drugs Gokhan Can · Nov 20, 2024 · Facebook
  11. Harvard Gazette on JoAnn Manson: VITAL trial of vitamin D and omega-3 in 25,000 adults Louis Nervegna · Jun 13, 2025 · Facebook
  12. ACC 2025 data strengthen the case for icosapent ethyl on top of low LDL Louis Nervegna · May 21, 2025 · Facebook
  13. Evidence that plaque can shrink: CENIT, PRECISE-IVUS, ZEUS, EVAPORATE and GLAGOV Louis Nervegna · Jun 25, 2025 · Facebook
  14. Plaque reduction: statins, PCSK9 inhibitors and ezetimibe have the strongest evidence Gokhan Can · May 18, 2024 · Facebook
  15. At least six strategies have reversed plaque in randomized trials Louis Nervegna · Aug 12, 2026 · Facebook
  16. Medication strategies that have regressed arterial plaque in high-quality RCTs Louis Nervegna · Aug 12, 2025 · Facebook
  17. Gokhan's evidence review of proven ways to reverse arterial plaque Louis Nervegna · Jul 21, 2026 · Facebook
  18. Does fish oil cause or prevent Afib? It may depend on dose and risk level Louis Nervegna · May 28, 2024 · Facebook
  19. Higher stored EPA linked to 36% lower bleeding stroke risk in a 21-year Danish study Louis Nervegna · Nov 09, 2026 · Facebook
  20. Fish oil dosing: aiming for 3 g EPA and 1 g DHA per day Gokhan Can · Nov 07, 2024 · Facebook
  21. Low omega-3 index (below 4%) linked to mortality risk like smoking, observational data Louis Nervegna · Sep 05, 2025 · Facebook
  22. Low omega-3 index (<4%) linked to mortality risk comparable to smoking in Framingham data Louis Nervegna · Jul 21, 2025 · Facebook
  23. Framingham data link a high omega-3 index to about 5 more years of life expectancy Louis Nervegna · Dec 03, 2025 · Facebook
  24. Rhonda Patrick on micronutrient deficiencies and exercise for healthy aging Gokhan Can · Mar 08, 2024 · Facebook
  25. Omega-3 index described as a heart disease risk factor, possibly stronger than cholesterol Louis Nervegna · Sep 02, 2024 · Facebook
  26. Peter Attia's current supplement stack Gokhan Can · Nov 23, 2023 · Facebook
  27. Bill Harris: oxidized fish oil is probably not harmful, only slightly less effective Louis Nervegna · Apr 08, 2026 · Facebook
  28. Super-oxidized fish oil fed for 7 weeks caused no harm in human trial Louis Nervegna · Sep 17, 2026 · Facebook
  29. Human trials: omega-6 and oxidized fish oil do not raise oxidation or inflammation markers Louis Nervegna · Sep 18, 2026 · Facebook
  30. PREVENT-E4: 2 g/day DHA did not slow cognitive decline in 365 at-risk older adults Louis Nervegna · Jun 19, 2026 · Facebook
  31. High-dose DHA did not slow cognitive decline in 2-year APOE4 trial, but reached the brain Louis Nervegna · Jun 27, 2026 · Facebook
  32. Fish oil and cognitive decline finding is likely reverse causality, says Yassine Louis Nervegna · May 14, 2026 · Facebook
  33. Rutgers trial tests plant omega-3 ALA for early Alzheimer's in APOE4 carriers Louis Nervegna · May 14, 2026 · Facebook
  34. Fuhrman: vegans should supplement algae-based DHA and EPA for brain protection Louis Nervegna · Mar 18, 2026 · Facebook
  35. 1 g/day omega-3 slowed epigenetic aging about 3 months in the 2,147-person DO-HEALTH trial Louis Nervegna · Feb 03, 2025 · Facebook
  36. DO-HEALTH: omega-3 slowed epigenetic aging clocks in older adults Louis Nervegna · Aug 01, 2026 · Facebook
  37. DO-HEALTH: vitamin D, omega-3 and exercise together linked to lower cancer risk Louis Nervegna · Dec 25, 2025 · Facebook
  38. DO-HEALTH: vitamin D, omega-3 and exercise cut invasive cancer risk 61% in adults 70+ Louis Nervegna · Dec 09, 2025 · Facebook
  39. VITAL: vitamin D3 2,000 IU slowed telomere shortening ~140 base pairs over 4 years Louis Nervegna · Jun 29, 2025 · Facebook
  40. Omega-3 at 1-2 g/day reduced PMS severity in a 2022 meta-analysis of 8 RCTs Louis Nervegna · Jun 27, 2026 · Facebook
  41. Review of 33 systematic studies finds little evidence omega-3 supplements build muscle Louis Nervegna · Mar 14, 2025 · Facebook
  42. Krill oil preserved muscle and strength during weight loss in an 8-week RCT Louis Nervegna · Jul 21, 2025 · Facebook
  43. Fish oil absorption ranges 20-90%, depending on the form and the fat content of the meal Louis Nervegna · May 14, 2026 · Facebook
  44. 2025 ACC statement: inflammation in ASCVD is compelling and clinically actionable Louis Nervegna · Sep 30, 2025 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary